Targeting the CD22 receptor on human B-cell lymphomas with RNA damaging agents.

被引：0
|
作者：
Newton, DL
Mikulski, SM
Sausville, EA
Rybak, SM
机构：
[1] NCI, Frederick Canc Res & Dev Ctr, DCTD, DTP, Frederick, MD 21702 USA
[2] Alfacell Corp, Bloomfield, NJ 07003 USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
469
引用
收藏
页码：4560S / 4560S
页数：1
相关论文
共 50 条
  • [21] EPRATUZUMAB, AN ANTIBODY TARGETING CD22 ON B CELLS, INDUCES PHOSPHOPROTEIN CHANGES FOLLOWING B-CELL RECEPTOR ACTIVATION IN VITRO
    Lumb, S.
    Torbett, N.
    Vendrell, I.
    Turner, H.
    Page, M.
    Hales, P.
    Maloney, A.
    Vanhaesebroeck, B.
    Cutillas, P.
    Shock, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 179 - 179
  • [22] Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
    Sieger, N.
    Fleischer, S. J.
    Reiter, K.
    Mei, H. E.
    Shock, A.
    Burmester, G.
    Daridon, C.
    Dorner, T.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S749 - S749
  • [23] A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    Pagel, John M.
    Orgun, Nural
    Hamlin, Donald K.
    Wilbur, D. Scott
    Gooley, Theodore A.
    Gopal, Ajay K.
    Park, Steven I.
    Green, Damian J.
    Lin, Yukang
    Press, Oliver W.
    BLOOD, 2009, 113 (20) : 4903 - 4913
  • [24] IN VIVO EFFECTS OF EPRATUZUMAB, A MONOCLONAL ANTIBODY TARGETING HUMAN CD22, ON B CELL FUNCTION IN HUMAN CD22 KNOCK-IN (HUKI) MICE
    Brandl, C.
    Oezgoer, L.
    Woehner, M.
    Shock, A.
    Nitschke, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 811 - 811
  • [25] In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
    Brandl, Carolin
    Oezgoer, Lamia
    Woehner, Miriam
    Shock, Anthony
    Nitschke, Lars
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S855 - S856
  • [26] TYROSINE PHOSPHORYLATION OF CD22 DURING B-CELL ACTIVATION
    SCHULTE, RJ
    CAMPBELL, MA
    FISCHER, WH
    SEFTON, BM
    SCIENCE, 1992, 258 (5084) : 1001 - 1004
  • [27] Expression and function of CD22, a B-cell restricted molecule
    Moyron-Quiroz, JE
    Partida-Sánchez, S
    Donís-Hernández, R
    Sandoval-Montes, C
    Santos-Argumedo, L
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (04) : 343 - 351
  • [28] ASSOCIATION OF CD22 WITH THE MOUSE SURFACE IGM (SIGM) B-CELL RECEPTOR (BCR) COMPLEX
    LAW, CL
    CHANDRAN, KA
    DRAVES, KE
    LEPRINCE, C
    CLARK, EA
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A254 - A254
  • [29] HEMATOPOIETIC-CELL PHOSPHATASE IS RECRUITED TO CD22 FOLLOWING B-CELL ANTIGEN RECEPTOR LIGATION
    LANKESTER, AC
    VANSCHIJNDEL, GMW
    VANLIER, RAW
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (35) : 20305 - 20308
  • [30] Comparison of biodistributions and therapeutic efficacies of pretargeted radioimmunoconjugates targeting the CD20, CD22, and DR molecules on human B cell lymphomas.
    Pantelias, A
    Pagel, JM
    Hedin, N
    Lin, Y
    Axworthy, D
    Theodore, LJ
    Press, OW
    BLOOD, 2005, 106 (11) : 181A - 182A
12345